Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL724402 | 0.87 | EGFR (0.51) | EGFRMAPTSMN1; SMN2MEN1NPC1 | |
| SCHEMBL17251706 | 0.77 | HDAC3 (0.58) | EGFRHDAC3HDAC1HDAC7HDAC8 | |
| SCHEMBL1684005 | 0.76 | MAPT (0.50) | EGFRMAPTSMN1; SMN2HDAC3HDAC1 | |
| SCHEMBL27888206 | 0.73 | EGFR (0.47) | EGFRMAPTSMN1; SMN2MEN1NPC1 | |
| SCHEMBL23734478 | 0.68 | BRAF (0.45) | MAPTSMN1; SMN2MEN1NPC1NFKB1 | |
| SCHEMBL6199287 | 0.68 | KDM4E (0.56) | MAPTSMN1; SMN2MEN1RAB9AKMT2A | |
| SCHEMBL19929805 | 0.68 | HDAC3 (0.54) | EGFRHDAC3HDAC1HDAC7HDAC8 | |
| SCHEMBL8881538 | 0.67 | KDM4E (0.44) | MAPTSMN1; SMN2MEN1NPC1RAB9A | |
| SCHEMBL18562034 | 0.67 | HDAC3 (0.58) | EGFRHDAC3HDAC1HDAC7HDAC8 | |
| SCHEMBL724442 | 0.67 | TSHR (0.44) | SMN1; SMN2MEN1KMT2AHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3708164-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3139919-B1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS INC (US) | 2020-06-03 | — | — | EP | disclosed |
| US-9981915-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180118693-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20170057930-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118693-A1 | COMPOUNDS FOR TREATMENT OF CANCER | TP53, TUBB1, TUBB6 | EGFR 1415/4885MAPT 699/4885SMN1; SMN2 4252/4885 |
| US-20170057930-A1 | COMPOUNDS FOR TREATMENT OF CANCER | TP53, TUBB1, TUBB6 | EGFR 1415/4885MAPT 699/4885SMN1; SMN2 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.